Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox in MDS with Transfusional Iron Overload
NCT00940602Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in Transfusional Iron Overload (TIO) comparing Deferasirox with Placebo (2 arms). Primary endpoint: Event-free Survival. Started Mar 2010; status: completed.
02
Drugs
deferasirox
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT00940602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940602.